Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Cubilin receptor is a large, 460 kDa peripheral membrane protein that serves as a multi-ligand endocytic receptor, primarily localized in the apical membrane of the ileum and the renal proximal tubules (UniProt P35548). It is unique among receptors because it lacks a transmembrane domain and a cytoplasmic tail, necessitating an interaction with the transmembrane protein Amnionless to form the functional CUBAM complex for membrane anchoring and internalization (PubMed: 15190073). Its primary physiological roles include the absorption of the intrinsic factor-vitamin B12 complex in the intestine and the reabsorption of filtered proteins, such as albumin, transferrin, and vitamin-binding proteins, from the primary urine in the kidney (PubMed: 10545152). Mutations in the CUBN gene are the underlying cause of Imerslund-Gräsbeck syndrome, which presents as megaloblastic anemia due to B12 deficiency and persistent proteinuria (OMIM: 211200). While there are currently no FDA-approved drugs that specifically target cubilin for therapeutic modulation, it is a subject of intense research in nephrology for its role in albuminuria and as a potential portal for the targeted delivery of drugs to the renal proximal tubule (PubMed: 28655776).
Mediates the endocytosis of various ligands, including the intrinsic factor-vitamin B12 complex and albumin, by forming a functional heterodimeric complex (CUBAM) with the transmembrane protein Amnionless.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Cubilin receptor (CUBN).